Trial Profile
Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Wound infections
- Focus Pharmacokinetics
- 31 Jul 2018 Status changed from recruiting to completed.
- 23 Feb 2017 Status changed from not yet recruiting to recruiting.
- 08 Dec 2015 New trial record